233 related articles for article (PubMed ID: 27482646)
1. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.
Vijayvergia N; Boland PM; Handorf E; Gustafson KS; Gong Y; Cooper HS; Sheriff F; Astsaturov I; Cohen SJ; Engstrom PF
Br J Cancer; 2016 Aug; 115(5):564-70. PubMed ID: 27482646
[TBL] [Abstract][Full Text] [Related]
2. Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor.
Takizawa N; Ohishi Y; Hirahashi M; Takahashi S; Nakamura K; Tanaka M; Oki E; Takayanagi R; Oda Y
Hum Pathol; 2015 Dec; 46(12):1890-900. PubMed ID: 26434631
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
4. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
5. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
6. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
Yachida S; Vakiani E; White CM; Zhong Y; Saunders T; Morgan R; de Wilde RF; Maitra A; Hicks J; Demarzo AM; Shi C; Sharma R; Laheru D; Edil BH; Wolfgang CL; Schulick RD; Hruban RH; Tang LH; Klimstra DS; Iacobuzio-Donahue CA
Am J Surg Pathol; 2012 Feb; 36(2):173-84. PubMed ID: 22251937
[TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.
Vollbrecht C; Werner R; Walter RF; Christoph DC; Heukamp LC; Peifer M; Hirsch B; Burbat L; Mairinger T; Schmid KW; Wohlschlaeger J; Mairinger FD
Br J Cancer; 2015 Dec; 113(12):1704-11. PubMed ID: 26645239
[TBL] [Abstract][Full Text] [Related]
9. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours.
Samsom KG; Levy S; van Veenendaal LM; Roepman P; Kodach LL; Steeghs N; Valk GD; Wouter Dercksen M; Kuhlmann KFD; Verbeek WHM; Meijer GA; Tesselaar MET; van den Berg JG
Histopathology; 2021 Mar; 78(4):556-566. PubMed ID: 32931025
[TBL] [Abstract][Full Text] [Related]
10. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
11. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
12. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
13. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
[TBL] [Abstract][Full Text] [Related]
14. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.
Park HY; Kwon MJ; Kang HS; Kim YJ; Kim NY; Kim MJ; Min KW; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Lee HK
Hum Pathol; 2019 May; 87():83-94. PubMed ID: 30851333
[TBL] [Abstract][Full Text] [Related]
16. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
17. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
18. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
[TBL] [Abstract][Full Text] [Related]
19. Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S; Vanoli A
J Clin Pathol; 2014 Nov; 67(11):938-48. PubMed ID: 25053544
[TBL] [Abstract][Full Text] [Related]
20. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
